<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00571259</url>
  </required_header>
  <id_info>
    <org_study_id>SR001AL</org_study_id>
    <nct_id>NCT00571259</nct_id>
  </id_info>
  <brief_title>Prophylactic Antimicrobial Catheter Lock</brief_title>
  <acronym>ALLOCK</acronym>
  <official_title>Prophylactic Antimicrobial Catheter Lock in Hemodialysis Patients: A Randomized Controlled Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Satellite Healthcare</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Satellite Healthcare</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized, double blinded, prospective, multicenter, clinical trial of the use of&#xD;
      Heparin versus Gentamicin as a pos-dialysis catheter lock solution.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study is a randomized, double blinded, prospective, multicenter, clinical trial. All&#xD;
      patients requiring vascular access with a tunneled central venous catheter for hemodialysis&#xD;
      are eligible for enrollment. Patients will be randomized to receive either Heparin 1,000 U/ml&#xD;
      in a volume sufficient to fill the catheter length in both ports or to receive 4% Sodium&#xD;
      Citrate with Gentamicin 320 mcg/mL in a volume sufficient to fill the catheter length in both&#xD;
      ports.We hypothesize that the device related infection rate in the Citrate/Gentamicin group&#xD;
      will be less than the heparin arm.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2003</start_date>
  <completion_date type="Actual">January 2010</completion_date>
  <primary_completion_date type="Actual">January 2010</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of Device-related Bacteremia</measure>
    <time_frame>5 years</time_frame>
    <description>Positive blood cultures in a patient whose vascular access is a central venous catheter without another obvious source of infection</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of Catheter Clotting Measured as Requirement for tPA Usage to Maintain Blood Flow</measure>
    <time_frame>5 years</time_frame>
    <description>The rate of thrombolytic agent use required to maintain blood flow adequate for dialysis was used as an objective measure of clinically significant catheter clotting.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">303</enrollment>
  <condition>Bacteremia</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Catheter lock with heparin 1,000 units/mL</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Catheter lock with gentamicin 320 micrograms/mL in sodium citrate 4%</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Heparin 1000U/mL</intervention_name>
    <description>A volume sufficient to fill the catheter length will be instilled in both catheter ports post dialysis</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>4% Sodium Citrate with Gentamicin 320 mcg/mL</intervention_name>
    <description>A volume sufficient to fill the catheter length will be instilled in both catheter ports post dialysis</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Requires placement of a central venous catheter or currently has a central venous&#xD;
             catheter for hemodialysis access.&#xD;
&#xD;
          -  Must be at least 18 years old&#xD;
&#xD;
          -  Compliant with a dialysis treatment schedule&#xD;
&#xD;
          -  Plans to continue hemodialysis treatment and follow-up at the investigational site&#xD;
&#xD;
          -  Must be able to care for the exit site independently or have someone who is able to&#xD;
             care for the site for them&#xD;
&#xD;
          -  Must be able to sign the informed consent document&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  The subject who has had an infection associated with one or more positive blood&#xD;
             cultures is not eligible until 14 days after blood cultures have become negative and&#xD;
             clinical resolution of the episode has occurred&#xD;
&#xD;
          -  Active exit site or tunnel infection&#xD;
&#xD;
          -  Systemic or localized infection that is unresponsive to antibiotic therapy and/or is&#xD;
             life threatening&#xD;
&#xD;
          -  Known to have antibodies to heparin&#xD;
&#xD;
          -  Allergy to pork heparin&#xD;
&#xD;
          -  Allergy to gentamicin&#xD;
&#xD;
          -  Subject is pregnant&#xD;
&#xD;
          -  Known intravenous drug abuse&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Norman Coplon, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Satellite Healthcare, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Satellite Healthcare, Inc</name>
      <address>
        <city>Mountain View</city>
        <state>California</state>
        <zip>94041</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>December 10, 2007</study_first_submitted>
  <study_first_submitted_qc>December 10, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 11, 2007</study_first_posted>
  <results_first_submitted>March 15, 2021</results_first_submitted>
  <results_first_submitted_qc>September 21, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">September 22, 2021</results_first_posted>
  <last_update_submitted>September 21, 2021</last_update_submitted>
  <last_update_submitted_qc>September 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Sodium citrate</keyword>
  <keyword>Gentamicin</keyword>
  <keyword>Prophylaxis</keyword>
  <keyword>Hemodialysis</keyword>
  <keyword>Central venous catheter</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bacteremia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gentamicins</mesh_term>
    <mesh_term>Heparin</mesh_term>
    <mesh_term>Citric Acid</mesh_term>
    <mesh_term>Sodium Citrate</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>1: Heparin Lock</title>
          <description>Dialysis Catheter locked with heparin 1,000 units/mL.&#xD;
Heparin 1000U/mL: A volume sufficient to fill the catheter length will be instilled in both catheter ports post dialysis</description>
        </group>
        <group group_id="P2">
          <title>2: Gentamicin Lock</title>
          <description>Dialysis Catheter locked with gentamicin 320 micrograms/mL in sodium citrate 4%.&#xD;
4% Sodium Citrate with Gentamicin 320 mcg/mL: A volume sufficient to fill the catheter length will be instilled in both catheter ports post dialysis</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="148"/>
                <participants group_id="P2" count="155"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="144"/>
                <participants group_id="P2" count="141"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>All adult patients with either newly placed or existing tunneled cuffed catheters were eligible for enrollment. Patients were excluded if they had an active exit-site or tunnel infection or other systemic or localized infection that was unresponsive to antibiotic therapy and/or was life-threatening. Eligible patients were randomly assigned 1:1 to treatment or control groups.</population>
      <group_list>
        <group group_id="B1">
          <title>1: Heparin Lock</title>
          <description>Dialysis catheter locked with heparin 1,000 units/mL post-dialysis.&#xD;
Heparin 1000U/mL: A volume sufficient to fill the catheter length will be instilled in both catheter ports post dialysis</description>
        </group>
        <group group_id="B2">
          <title>2: Gentamicin Lock</title>
          <description>Dialysis catheter locked with gentamicin 320 micrograms/mL in sodium citrate 4% post-dialysis.&#xD;
4% Sodium Citrate with Gentamicin 320 mcg/mL: A volume sufficient to fill the catheter length will be instilled in both catheter ports post dialysis</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="148"/>
            <count group_id="B2" value="155"/>
            <count group_id="B3" value="303"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="62.8" spread="16.8"/>
                    <measurement group_id="B2" value="63.4" spread="15.6"/>
                    <measurement group_id="B3" value="63.1" spread="14.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="81"/>
                    <measurement group_id="B2" value="76"/>
                    <measurement group_id="B3" value="157"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="67"/>
                    <measurement group_id="B2" value="79"/>
                    <measurement group_id="B3" value="146"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="148"/>
                    <measurement group_id="B2" value="155"/>
                    <measurement group_id="B3" value="303"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Diabetes</title>
          <description>Percent of subjects in each cohort who were diabetic.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="86"/>
                    <measurement group_id="B2" value="85"/>
                    <measurement group_id="B3" value="171"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Dialysis vintage in Months</title>
          <description>The number of months the subject has been on hemodialysis.</description>
          <units>months</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="44.3" lower_limit="1.1" upper_limit="131.8"/>
                    <measurement group_id="B2" value="42.4" lower_limit="0" upper_limit="198.5"/>
                    <measurement group_id="B3" value="43.32" lower_limit="0" upper_limit="198.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Incident Catheters</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Catheter site</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Internal Jugular</title>
                  <measurement_list>
                    <measurement group_id="B1" value="104"/>
                    <measurement group_id="B2" value="113"/>
                    <measurement group_id="B3" value="217"/>
                  </measurement_list>
                </category>
                <category>
                  <title>External Jugular</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="24"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Femoral</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Subclavian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="13"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown</title>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Rate of Device-related Bacteremia</title>
        <description>Positive blood cultures in a patient whose vascular access is a central venous catheter without another obvious source of infection</description>
        <time_frame>5 years</time_frame>
        <population>Episodes of catheter related infections in each group throughout the study.</population>
        <group_list>
          <group group_id="O1">
            <title>1: Heparin Lock</title>
            <description>Dialysis Catheter locked with heparin 1,000 units/mL in a volume sufficient to fill the catheter length and instilled in both catheter ports post-dialysis.&#xD;
Heparin 1000U/mL: A volume sufficient to fill the catheter length will be instilled in both catheter ports post dialysis</description>
          </group>
          <group group_id="O2">
            <title>2: Gentamicin Lock</title>
            <description>Dialysis Catheter locked with gentamicin 320 micrograms/mL in sodium citrate 4% in a volume sufficient to fill the catheter length and instilled in both catheter ports post-dialysis.&#xD;
4% Sodium Citrate with Gentamicin 320 mcg/mL: A volume sufficient to fill the catheter length will be instilled in both catheter ports post dialysis</description>
          </group>
        </group_list>
        <measure>
          <title>Rate of Device-related Bacteremia</title>
          <description>Positive blood cultures in a patient whose vascular access is a central venous catheter without another obvious source of infection</description>
          <population>Episodes of catheter related infections in each group throughout the study.</population>
          <units>Number of infections</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="148"/>
                <count group_id="O2" value="155"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30"/>
                    <measurement group_id="O2" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Rate of Catheter Clotting Measured as Requirement for tPA Usage to Maintain Blood Flow</title>
        <description>The rate of thrombolytic agent use required to maintain blood flow adequate for dialysis was used as an objective measure of clinically significant catheter clotting.</description>
        <time_frame>5 years</time_frame>
        <population>tPA use/1,000 catheter-days</population>
        <group_list>
          <group group_id="O1">
            <title>1: Heparin Lock</title>
            <description>Dialysis Catheter locked with heparin 1,000 units/mL in a volume sufficient to fill the catheter length and instilled in both catheter ports post-dialysis.</description>
          </group>
          <group group_id="O2">
            <title>2: Gentamicin Lock</title>
            <description>Dialysis Catheter locked with gentamicin 320 micrograms/mL in sodium citrate 4% in a volume sufficient to fill the catheter length and instilled in both catheter ports post-dialysis.</description>
          </group>
        </group_list>
        <measure>
          <title>Rate of Catheter Clotting Measured as Requirement for tPA Usage to Maintain Blood Flow</title>
          <description>The rate of thrombolytic agent use required to maintain blood flow adequate for dialysis was used as an objective measure of clinically significant catheter clotting.</description>
          <population>tPA use/1,000 catheter-days</population>
          <units>tPA use/1,000 catheter-days</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="148"/>
                <count group_id="O2" value="155"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.42"/>
                    <measurement group_id="O2" value="2.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>5 years</time_frame>
      <group_list>
        <group group_id="E1">
          <title>1: Heparin Lock</title>
          <description>Dialysis Catheter locked with heparin 1,000 units/mL.&#xD;
Heparin 1000U/mL: A volume sufficient to fill the catheter length will be instilled in both catheter ports post dialysis</description>
        </group>
        <group group_id="E2">
          <title>2: Gentamicin Lock</title>
          <description>Dialysis Catheter locked with gentamicin 320 micrograms/mL in sodium citrate 4%.&#xD;
4% Sodium Citrate with Gentamicin 320 mcg/mL: A volume sufficient to fill the catheter length will be instilled in both catheter ports post dialysis</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="148"/>
                <counts group_id="E2" subjects_affected="27" subjects_at_risk="155"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="148"/>
                <counts group_id="E2" subjects_affected="27" subjects_at_risk="155"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>ESRD Related Death</sub_title>
                <description>Serious adverse events were deaths of dialysis subjects which were related to ESRD or the subject's comorbid conditions, not study related.</description>
                <counts group_id="E1" events="25" subjects_affected="25" subjects_at_risk="148"/>
                <counts group_id="E2" events="27" subjects_affected="27" subjects_at_risk="155"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="155"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>The requirement for dialysis facility staff to prepare the treatment intervention prevented a completely blinded study.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Veronica Legg, MS: Director of Research Business</name_or_title>
      <organization>Satellite Healthcare, Inc.</organization>
      <phone>360-607-6892</phone>
      <email>leggv@satellitehealth.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

